Investment
Features
FeesSafety
Academy
More
Pluang+

Plasma unlocks 1.81B XPL tokens for team and investors on Sept 25, 2026, marking a major supply increase.

Protocol Fundamentals
01 Sep 2026
CryptoTicker
View Source
Neutral
pluang ai news

On September 25, 2026, Plasma will unlock 1.81 billion XPL tokens held by the team and investors after a one-year lock-up since the mainnet beta launch. This release represents about 65% of the circulating supply at that time and is part of a vesting schedule that will continue monthly until September 2028. The unlock increases the circulating supply from around 2.78 billion to about 4.67 billion XPL tokens, impacting market dynamics but not necessarily causing immediate selling pressure. The event is significant for investors tracking supply changes and tokenomics but does not guarantee price movement as unlocked tokens are not automatically sold.

More News

Medtronic beats Q3 earnings and revenue estimates, boosts outlook with $700M investment in Heart Tech and Robotics.

Medtronic beats Q3 earnings and revenue estimates, boosts outlook with $700M investment in Heart Tech and Robotics.

Medtronic reported Q3 earnings per share of $1.45, surpassing estimates of $1.39, and revenue of $9.76 billion, above the $9.55 billion consensus. The strong financial results reflect broad demand for its cardiovascular devices. The company raised it...

Company Fundamentals
Bullish
1 hour ago
Dell Technologies set for record Q2 earnings driven by AI server demand and strong revenue growth.

Dell Technologies set for record Q2 earnings driven by AI server demand and strong revenue growth.

Dell Technologies is expected to report record second-quarter earnings with EPS around $4.91 and revenue near $44.89 billion, fueled by high demand for its AI-optimized servers. This would mark a significant increase from last year's $29.78 billion a...

Company Fundamentals
Bullish
1 hour ago
Protagonist Therapeutics' price target raised to $180 after FDA approves new drug MIMRYLO.

Protagonist Therapeutics' price target raised to $180 after FDA approves new drug MIMRYLO.

Protagonist Therapeutics saw its stock price target raised to $180 by Barclays following the FDA approval of MIMRYLO, a first-in-class drug for polycythemia vera. The approval was based on strong Phase 3 trial results with 76.9% patient response, tri...

Analyst Insights
Bullish
2 hours ago
Hercules Capital upgraded to Buy by UBS, highlighting strong financials and 11.1% dividend yield.

Hercules Capital upgraded to Buy by UBS, highlighting strong financials and 11.1% dividend yield.

UBS upgraded Hercules Capital's rating from Neutral to Buy, reflecting confidence in the company's strong financial stability and growth prospects. Hercules Capital, a specialty finance firm supporting tech and life sciences startups, boasts a BBB+ c...

Analyst Insights
Bullish
3 hours ago
Seeking Alpha highlights 12 lesser-known stocks weekly to inspire fresh investment ideas.

Seeking Alpha highlights 12 lesser-known stocks weekly to inspire fresh investment ideas.

Seeking Alpha's "The Undercovered Dozen" is a weekly series that spotlights 12 lesser-covered stocks with market caps over $100 million and limited recent coverage. The series aims to introduce investors to overlooked investment opportunities, encour...

Others
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App